Get Relief From Obstructive Sleep Apnea - Vivos Blog

Skip to content Skip to footer

VivosTherapeutic Close

Blog

FDA-Cleared Allergy and Sleep Technologies

Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth’s Groundbreaking FDA-Cleared Allergy and Sleep Technologies

Quarter Financial Results

Vivos Therapeutics Announces Exercise of Warrants for $4.64 Million Gross Proceeds

Acquisition of The Sleep Centers of Nevada

Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan

Vivos Therapeutics 2025 3rd Quarter Growth

Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

Q3 Earnings Release

Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD

Vivos Therapeutics Releases Additional Clinical Data Showing Marked Improvement in Pediatric ADHD from Use of Vivos DNA Device

Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment

Q2-Earnings-Release

Vivos Therapeutics Reports Second Quarter 2025 Financial Results and Provides Operational Update

Vivos First Quarter 2025 Financial Results

Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call